Data as of Dec 19
| +0.0199 / +2.76%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 3.25, with a high estimate of 3.50 and a low estimate of 3.00. The median estimate represents a +339.25% increase from the last price of 0.74.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.